| 31.19 -0.61 (-1.92%) | 03-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 40.3 | 1-year : | 47.07 |
| Resists | First : | 34.5 | Second : | 40.3 |
| Pivot price | 30.2  |
|||
| Supports | First : | 27.14 |
Second : | 22.6 |
| MAs | MA(5) : | 30.49 |
MA(20) : | 30.18 |
| MA(100) : | 26.57 |
MA(250) : | 23.84 |
|
| MACD | MACD : | 1.1 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 60.5 |
D(3) : | 54.9 |
| RSI | RSI(14): 60.7 |
|||
| 52-week | High : | 34.5 | Low : | 14.39 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLDX ] has closed below upper band by 22.2%. Bollinger Bands are 29.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 31.99 - 32.15 | 32.15 - 32.28 |
| Low: | 30.13 - 30.3 | 30.3 - 30.42 |
| Close: | 30.92 - 31.21 | 31.21 - 31.42 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Mon, 23 Mar 2026
Celldex Therapeutics stock hits 52-week high at 32.8 USD - Investing.com
Mon, 23 Mar 2026
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year High Following Analyst Upgrade - MarketBeat
Mon, 23 Mar 2026
Celldex Therapeutics (NASDAQ:CLDX) Upgraded at Wolfe Research - MarketBeat
Mon, 23 Mar 2026
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Sun, 15 Mar 2026
Celldex Therapeutics, Inc. $CLDX Shares Sold by Commodore Capital LP - MarketBeat
Fri, 13 Mar 2026
Celldex Therapeutics (CLDX) Is Up 5.7% After New Phase 2 Barzolvolimab Data in Inducible Urticaria - Sahm
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 67 (M) |
| Held by Insiders | 6.042e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 9,030 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.8399e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | 27.2 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 1.54e+006 % |
| Gross Profit (p.s.) | -71.2 |
| Sales Per Share | -32.24 |
| EBITDA (p.s.) | -1.93278e+008 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.97 |
| Price to Cash Flow | 4.96 |
| Dividend | 0 |
| Forward Dividend | 9.18e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|